Literature DB >> 20650182

Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures.

L A Vernetti1, J R Macdonald, D G Pegg.   

Abstract

PD132301-2, a novel inhibitor of acyl-CoA: cholesterol acyltransferase, was previously shown to be an inhibitor of mitochondrial respiration and an adrenal toxicant in several species. To investigate potential mechanisms of tissue-specific toxicity in vivo, dog adrenocortical and hepatocyte cell cultures were exposed to 0.01-30 mum PD132301-2 for 0-24 hr. Cell viability was assessed by neutral red uptake or release assays. Cytotoxicity was observed in adrenocortical cells at 0.01 mum or above after 2hr of exposure, while 30 mum was not toxic to hepatocytes after 24 hr of exposure. Decreases in adrenocortical cell viability were attenuated in the presence of 20 mm fructose, a glycolytic substrate, and fructose protection was in turn blocked by the glycolytic inhibitor NaF (1 mm). In contrast, PD132301-2-induced hepatocellular toxicity was evident only following pretreatment with NaF or metyrapone, a broad-spectrum cytochrome P-450 inhibitor. With either co-treatment, hepatocyte viability was reduced 50% after 6 hr at 1 mum or more PD132301-2. These data indicate that the relative sensitivity of adrenocortical cells to the cytotoxic effects of PD132301-2 may be due, in part, to their relative lack of the metabolic detoxification and glycolytic reserve capacities that appear to protect hepatocytes from PD132301-2 toxicity.

Entities:  

Year:  1996        PMID: 20650182     DOI: 10.1016/0887-2333(95)00102-6

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  2 in total

1.  Synthesis and Evaluation of 11C- and 18F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents.

Authors:  James R Hill; Xia Shao; Jay S Wright; Jenelle Stauff; Phillip S Sherman; Janna Arteaga; Ka Kit Wong; Benjamin L Viglianti; Peter J H Scott; Allen F Brooks
Journal:  ACS Med Chem Lett       Date:  2020-04-30       Impact factor: 4.345

2.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.